{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T19:38:52Z","timestamp":1789501132181,"version":"build-2803163510"},"reference-count":24,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T00:00:00Z","timestamp":1739923200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nefrolog\u00eda (English Edition)"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.nefroe.2025.02.010","type":"journal-article","created":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T16:31:44Z","timestamp":1741710704000},"page":"214-227","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Evidence for the use of a nonsteroidal mineralocorticoid receptor antagonist for the treatment of chronic kidney disease"],"prefix":"10.1016","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-5919-5123","authenticated-orcid":false,"given":"Mariana","family":"Morais David Pli\u00e7as","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernardo","family":"Marques da Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edgar","family":"Avito Fernandes de Almeida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nefroe.2025.02.010_bib0245","first-page":"4","article-title":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","year":"2024","journal-title":"Kidney Int"},{"key":"10.1016\/j.nefroe.2025.02.010_bib0130","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1371\/journal.pone.0158765","article-title":"Global prevalence of chronic kidney disease \u2013 a systematic review and meta-analysis","volume":"11","author":"Hill","year":"2016","journal-title":"PLoS ONE"},{"key":"10.1016\/j.nefroe.2025.02.010_bib0135","unstructured":"Global Burden of Disease Genitourinary Expert Group (2017). Global Cardiovascular and Renal Outcomes of Reduced GFR. J Am Soc Nephrol 2017;28."},{"key":"10.1016\/j.nefroe.2025.02.010_bib0140","series-title":"Harrison's Princ. Intern. Med.","article-title":"Chronic kidney disease","author":"Harrison-Bargman","year":"2022"},{"key":"10.1016\/j.nefroe.2025.02.010_bib0145","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1159\/000515622","article-title":"Aldosterone and mineralocorticoid receptor signaling as determinants of cardiovascular and renal injury: from hans selye to the present","volume":"52","author":"Epstein","year":"2021","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.nefroe.2025.02.010_bib0150","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.kint.2019.02.030","article-title":"Mineralocorticoid receptor antagonists and kidney diseases: pathophysiological basis","volume":"96","author":"Barrera-Chimal","year":"2019","journal-title":"Kidney Int"},{"key":"10.1016\/j.nefroe.2025.02.010_bib0155","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1093\/eurheartj\/ehaa736","article-title":"Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine","volume":"42","author":"Agarwal","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.nefroe.2025.02.010_bib0160","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1093\/ajh\/hpy120","article-title":"Mineralocorticoid receptor and cardiovascular disease","volume":"31","author":"Buonafine","year":"2018","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.nefroe.2025.02.010_bib0165","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.bcp.2019.07.001","article-title":"The non-steroidal mineralocorticoid receptor antagonist finerenone prevents cardiac fibrotic remodeling","volume":"168","author":"Lavall","year":"2019","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.nefroe.2025.02.010_bib0170","doi-asserted-by":"crossref","unstructured":"KDIGO. KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int 2022;102:S1\u2013127. https:\/\/doi.org\/10.1016\/j.kint.2022.06.008.","DOI":"10.1016\/j.kint.2022.06.008"},{"key":"10.1016\/j.nefroe.2025.02.010_bib0175","unstructured":"DGAV DG de A e V. Anexo I Resumo Das Carater\u00edsticas Do Medicamento Kerendia 10mg comprimidos revestidos por pel\u00edcula Kerendia 20mg comprimidos revestidos por pel\u00edcula 2. 2020:5."},{"key":"10.1016\/j.nefroe.2025.02.010_bib0180","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nefroe.2025.02.010_bib0185","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nefroe.2025.02.010_bib0190","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.nefroe.2025.02.010_bib0195","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.2337\/dc22-0294","article-title":"Finerenone in patients with chronic kidney disease and type 2 diabetes by sodium\u2013glucose cotransporter 2 inhibitor treatment: the FIDELITY analysis","volume":"45","author":"Rossing","year":"2022","journal-title":"Diabetes Care"},{"key":"10.1016\/j.nefroe.2025.02.010_bib0200","doi-asserted-by":"crossref","first-page":"110161","DOI":"10.1016\/j.diabres.2022.110161","article-title":"Cardiovascular and kidney outcomes of combination therapy with sodium-glucose cotransporter-2 inhibitors and mineralocorticoid receptor antagonists in patients with type 2 diabetes and chronic kidney disease: a systematic review and network meta-analysis","volume":"194","author":"Tsukamoto","year":"2022","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.nefroe.2025.02.010_bib0205","first-page":"1","article-title":"Additive effects of dapagliflozin and finerenone on albuminuria in non-diabetic CKD: an open-label randomized clinical trial","volume":"17","author":"M\u00e5rup","year":"2023","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.nefroe.2025.02.010_bib0210","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2407107","article-title":"Finerenone in heart failure with mildly reduced or preserved ejection fraction","author":"Solomon","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nefroe.2025.02.010_bib0215","unstructured":"Pharmaceuticals and Medical Devices Agency (PMDA). Minnebro Tablets_Daiichi Sankyo Company, Limited_Review Report 2018."},{"key":"10.1016\/j.nefroe.2025.02.010_bib0220","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.2215\/CJN.06870520","article-title":"Esaxerenone (CS-3150) in patients with type 2 diabetes and microalbuminuria (ESAX-DN): phase 3 randomized controlled clinical trial","volume":"15","author":"Ito","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2025.02.010_bib0225","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1007\/s10157-021-02075-y","article-title":"Efficacy and safety of esaxerenone (CS-3150) in Japanese patients with type 2 diabetes and macroalbuminuria: a multicenter, single-arm, open-label phase III study","volume":"25","author":"Ito","year":"2021","journal-title":"Clin Exp Nephrol"},{"key":"10.1016\/j.nefroe.2025.02.010_bib0230","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1007\/s10157-020-01963-z","article-title":"Apararenone in patients with diabetic nephropathy: results of a randomized, double-blind, placebo-controlled phase 2 dose\u2013response study and open-label extension study","volume":"25","author":"Wada","year":"2021","journal-title":"Clin Exp Nephrol"},{"key":"10.1016\/j.nefroe.2025.02.010_bib0235","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1161\/HYPERTENSIONAHA.121.17073","article-title":"Effect of KBP-5074 on blood pressure in advanced chronic kidney disease: results of the BLOCK-CKD study","volume":"78","author":"Bakris","year":"2021","journal-title":"Hypertension"},{"key":"10.1016\/j.nefroe.2025.02.010_bib0240","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1161\/HYPERTENSIONAHA.120.15199","article-title":"Mineralocorticoid receptor antagonists for hypertension management in advanced chronic kidney disease: BLOCK-CKD trial","volume":"76","author":"Bakris","year":"2020","journal-title":"Hypertension"}],"container-title":["Nefrolog\u00eda (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2013251425000355?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2013251425000355?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T16:31:55Z","timestamp":1741710715000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2013251425000355"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S2013251425000355"],"URL":"https:\/\/doi.org\/10.1016\/j.nefroe.2025.02.010","relation":{},"ISSN":["2013-2514"],"issn-type":[{"value":"2013-2514","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evidence for the use of a nonsteroidal mineralocorticoid receptor antagonist for the treatment of chronic kidney disease","name":"articletitle","label":"Article Title"},{"value":"Nefrolog\u00eda (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nefroe.2025.02.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Sociedad Espa\u00f1ola de Nefrolog\u00eda. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}